1. Home
  2. DTST vs EDSA Comparison

DTST vs EDSA Comparison

Compare DTST & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Data Storage Corporation

DTST

Data Storage Corporation

HOLD

Current Price

$3.77

Market Cap

8.5M

Sector

Technology

ML Signal

HOLD

Logo Edesa Biotech Inc.

EDSA

Edesa Biotech Inc.

HOLD

Current Price

$5.72

Market Cap

7.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DTST
EDSA
Founded
2001
2015
Country
United States
Canada
Employees
55
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.5M
7.5M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
DTST
EDSA
Price
$3.77
$5.72
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
N/A
$5.00
AVG Volume (30 Days)
11.1K
4.1M
Earning Date
05-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.31
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.94
$0.72
52 Week High
$5.44
$9.37

Technical Indicators

Market Signals
Indicator
DTST
EDSA
Relative Strength Index (RSI) 48.41 53.69
Support Level $3.95 $1.69
Resistance Level $4.32 $9.06
Average True Range (ATR) 0.20 1.14
MACD 0.01 -0.35
Stochastic Oscillator 62.99 19.03

Price Performance

Historical Comparison
DTST
EDSA

About DTST Data Storage Corporation

Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc; CloudFirst Europe Ltd and CloudFirst Technologies Corporation and Corporate. It generates maximum revenue from the CloudFirst Technologies Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.

About EDSA Edesa Biotech Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

Share on Social Networks: